VANCOUVER, British Columbia & SEATTLE, Wash., October 04, 2022--Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reminds shareholders that the deadline for voting FOR the Company’s plan to become a Delaware corporation (the "Redomicile") is 9:00 a.m., Pacific Time, on October 5, 2022. If you require assistance voting your proxy, please contact Kingsdale Advisors at 1-855-476-7981 (within North Ameri
VANCOUVER, British Columbia & SEATTLE, October 03, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences:
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.